{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009570","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.150195+00:00","generated_at":"2026-05-22T00:55:27.460711+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Imunon Q1 net loss $4.1M; cash only through late Q2 2025; Phase 3 ovarian cancer trial initiated","bullets":["Net loss $4.1M ($0.28 per share) vs $4.9M ($0.52 per share) in Q1 2024; operating expenses down 18%.","Cash and equivalents $2.9M as of 2025-03-31; company expects funding into late Q2 2025 only.","First trial site initiated for Phase 3 OVATION 3 study of IMNN-001 in advanced ovarian cancer.","Abstract for OVATION 2 updated survival analysis accepted for oral presentation at 2025 ASCO Annual Meeting.","Appointed Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer effective 2025-02-18."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009570","json":"https://secwatch.observer/filing/0001641172-25-009570.json","markdown":"https://secwatch.observer/filing/0001641172-25-009570.md","text":"https://secwatch.observer/filing/0001641172-25-009570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000164117225009570/0001641172-25-009570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000164117225009570/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:55:27.460711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}